Bevacizumab and FOLFIRI — Competitive Intelligence Brief

Bevacizumab and FOLFIRI (Bevacizumab and FOLFIRI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor, chemotherapy. Area: Oncology.

phase 2 VEGF inhibitor, chemotherapy VEGF-A Oncology Small molecule

Target snapshot

Bevacizumab and FOLFIRI (Bevacizumab and FOLFIRI) — Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente. Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while FOLFIRI is a chemotherapy regimen that includes irinotecan, a topoisomerase I inhibitor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bevacizumab and FOLFIRI TARGET	Bevacizumab and FOLFIRI	Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente	phase 2	VEGF inhibitor, chemotherapy	VEGF-A
intra-vitreal injection of Ranibizumab	intra-vitreal injection of Ranibizumab	Ain Shams University	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Lucentis (Treat and extend)	Lucentis (Treat and extend)	Retinal Consultants of Arizona	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A
Lucentis every 12 weeks	Lucentis every 12 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
Aflibercept Intravitreous Injection	Aflibercept Intravitreous Injection	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (placental growth factor)
Lucentis every 4 weeks	Lucentis every 4 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
aflibercept + FOLFIRI	aflibercept + FOLFIRI	CR-CSSS Champlain-Charles-Le Moyne	marketed	VEGF inhibitor (fusion protein) + chemotherapy combination	VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor, chemotherapy class)

1. Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente · 1 drug in this class